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Mutations of genes within the phosphatidylinositol-3-kinase (PI3K)-AKT-MTOR pathway are well known causes of brain over-
growth (megalencephaly) as well as segmental cortical dysplasia (such as hemimegalencephaly, focal cortical dysplasia and poly-
microgyria). Mutations of the AKT3 gene have been reported in a few individuals with brain malformations, to date. Therefore,
our understanding regarding the clinical and molecular spectrum associated with mutations of this critical gene is limited, with no
clear genotype–phenotype correlations. We sought to further delineate this spectrum, study levels of mosaicism and identify
genotype–phenotype correlations of AKT3-related disorders. We performed targeted sequencing of AKT3 on individuals with
these phenotypes by molecular inversion probes and/or Sanger sequencing to determine the type and level of mosaicism of
mutations. We analysed all clinical and brain imaging data of mutation-positive individuals including neuropathological analysis
in one instance. We performed ex vivo kinase assays on AKT3 engineered with the patient mutations and examined the phospho-
lipid binding proﬁle of pleckstrin homology domain localizing mutations. We identiﬁed 14 new individuals with AKT3 mutations
with several phenotypes dependent on the type of mutation and level of mosaicism. Our comprehensive clinical characterization,
and review of all previously published patients, broadly segregates individuals with AKT3 mutations into two groups: patients with
highly asymmetric cortical dysplasia caused by the common p.E17K mutation, and patients with constitutional AKT3 mutations
exhibiting more variable phenotypes including bilateral cortical malformations, polymicrogyria, periventricular nodular heterotopia
and diffuse megalencephaly without cortical dysplasia. All mutations increased kinase activity, and pleckstrin homology domain
mutants exhibited enhanced phospholipid binding. Overall, our study shows that activating mutations of the critical AKT3 gene
are associated with a wide spectrum of brain involvement ranging from focal or segmental brain malformations (such as hemi-
megalencephaly and polymicrogyria) predominantly due to mosaic AKT3 mutations, to diffuse bilateral cortical malformations,
megalencephaly and heterotopia due to constitutional AKT3 mutations. We also provide the ﬁrst detailed neuropathological
examination of a child with extreme megalencephaly due to a constitutional AKT3 mutation. This child has one of the largest
documented paediatric brain sizes, to our knowledge. Finally, our data show that constitutional AKT3 mutations are associated
with megalencephaly, with or without autism, similar to PTEN-related disorders. Recognition of this broad clinical and molecular
spectrum of AKT3 mutations is important for providing early diagnosis and appropriate management of affected individuals, and
will facilitate targeted design of future human clinical trials using PI3K-AKT pathway inhibitors.
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Introduction
Mutations of multiple genes within the phosphatidylinosi-
tol-3-kinase (PI3K)-AKT-MTOR pathway are well known
causes of brain overgrowth (megalencephaly) as well as
segmental cortical dysplasia (such as hemimegalencephaly,
focal cortical dysplasia and polymicrogyria) (Mirzaa et al.,
2013). The AKT complex is one of the most central mol-
ecules of this pathway that mediates many of its functions
by regulating several downstream pathways. Mutations of
the AKT3 gene have been reported in several patients to
date, including seven with constitutional mutations causing
megalencephaly with polymicrogyria (Riviere et al., 2012;
Jamuar et al., 2014; Nakamura et al., 2014; Harada et al.,
2015; Nellist et al., 2015; Negishi et al., 2017), and four
with the mosaic p.E17K mutation causing hemimegalence-
phaly (Lee et al., 2012; Poduri et al., 2012; Riviere et al.,
2012; Jansen et al., 2015). However, our understanding
regarding the clinical and molecular spectrum associated
with mutations of this critical gene is limited, with no
clear genotype–phenotype correlations. We therefore
sought to further delineate this spectrum, study levels of
mosaicism and identify genotype–phenotype correlations
of AKT3-related disorders. Here, we report 14 additional
patients with AKT3 mutations, including ﬁve with novel
mutations, who have more diverse phenotypes including
bilateral perisylvian polymicrogyria, bilateral periventricu-
lar nodular heterotopia, and megalencephaly with autism
but without any cortical dysplasia. We further provide the
ﬁrst detailed neuropathological characterization of extreme
megalencephaly caused by a constitutional AKT3 mutation
in a previously reported child (Riviere et al., 2012). This
child has one of the largest documented brain sizes in the
paediatric population, to our knowledge. We also report on
the ﬁrst child with bilateral multifocal cortical dysplasia
caused by the mosaic p.E17K mutation that was detectable
in skin-derived DNA. Our report substantially expands the
clinical, molecular and biochemical spectrum of
AKT3-related disorders and shows that activating muta-
tions of this critical gene are associated with a broader
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spectrum of developmental brain disorders. Knowledge of
this spectrum has important implications for the clinical
and molecular diagnosis of affected individuals, recurrence
risk counselling, and design of future human clinical trials
using PI3K-AKT-MTOR pathway inhibitors.
Materials and methods
Human subjects and samples
The Institutional Review Board at Seattle Children’s Hospital
approved this study. Individuals with megalencephaly and
focal malformations of cortical development were enrolled as
part of the developmental brain disorders research project.
Informed consent was obtained from subjects prior to enrol-
ment in the study. Genomic DNA was extracted from various
tissues (blood, saliva, skin ﬁbroblasts, brain) using standard
protocols. Brain tissue was obtained during clinically indicated
epilepsy surgery and appropriate samples were analysed by our
molecular methods.
Brain MRI
All subjects underwent brain MRI as part of their routine clin-
ical care. The investigators reviewed all images and relevant
clinical and phenotypic data.
Molecular methods
Multiplex targeted sequencing using single molecule
molecular inversion probes
We designed a pool of 26 single molecule molecular inversion
oligonucleotide probes (smMIPs) targeting the coding se-
quences of AKT3. SmMIPs tiled across a total of 2937bp of
genomic sequence, including 100% of the 1498 coding base
pairs of AKT3. Capture reactions (100 ng) were performed in
parallel. Massively parallel sequencing was performed on an
Illumina HiSeq system. Variant analysis was performed using
our previously published pipeline (Mirzaa et al., 2016a). All
missense, nonsense and splice site variants seen in two or more
capture events that had a frequency 51% in public databases
were retained for analysis.
Sanger sequencing
We performed conﬁrmation of constitutional mutations by
direct Sanger sequencing. PCR ampliﬁcation was done with
50 ng of genomic DNA using Taq DNA polymerase (Applied
Biosystems). Primers used to amplify the coding and ﬂanking
non-coding regions of AKT3 were designed using Primer 3.
Double-stranded DNA sequence analysis was done with the
BigDye Terminator chemistry (Applied Biosystems), and re-
actions were run on the ABI 3730_l Genetic Analyzer (Applied
Biosystems). Sequence chromatograms were analysed with
Mutation Surveyor software version 3.30. Sequences were
compared with normal control samples and the reference se-
quences for AKT3.
Overgrowth next generation sequencing
The multiplex polymerase chain reaction (PCR) panel was fol-
lowed by next generation sequencing (NGS) performed on an
Ion Torrent PGM platform. Allele detection limit was 1% at
1000 and 10% at 200 coverage. The threshold for muta-
tion detection was set at 10 without strand bias.
Cell culture
HEK293 cells were grown at 37C in 5% CO2 in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with 10%
foetal calf serum, L-GLN and antibiotics (penicillin-
streptomycin).
Expression vector, site-directed
mutagenesis, transfection and
immunoprecipitation
AKT3 expression vector was obtained from OriGene
(RC221051) as pCMV6-FLAG-MYC tagged Human cDNA
ORF Clone containing AKT3 (NM_005465). Patient muta-
tions were introduced using the QuikChange Site-Directed
Mutagenesis Kit (200518) from Agilent Technologies
(Stratagene) using custom-designed primer pairs (Supplemen-
tary Table 1). AKT3-containing plasmids were expressed and
transfected into HEK293 cells using calcium phosphate.
Brieﬂy, 5 mg of DNA was added to 61 ml of 2M CaCl2 in
500 ml ddH2O. This was added dropwise to 500 ml of 2
HBS (NaCl, Na2HPO4, HEPES pH to 7.0) before adding
to adherent cells, which were harvested 48 h later. Protein
extracts were prepared by incubating the cell pellet on ice
(1 h) in detergent extraction buffer [50 mM Tris HCl pH 7.5,
150mM NaCl, 2mM EDTA, 2mM EGTA, 50mM NaF,
25mM b-glycerolphosphate, 0.1mM Na-orthovanadate,
0.2% TritonTM X-100, 0.3% IGEPAL with protease inhibi-
tor cocktail (Roche)]. Insoluble material was precipitated by
centrifugation at 4C and the supernatant used for immuno-
precipitation. Ectopically expressed FLAG-tagged AKT3 was
then immunoprecipitated using ANTI-FLAG M2 Afﬁnity
Gel (A2220, Sigma-Aldrich) according to manufacturers’
instructions.
Kinase assay
AKT3-speciﬁc kinase assay using FLAG-captured ectopically
expressed AKT3 was assessed using the Non-radioactive
AKT Kinase Assay Kit (9840) from Cell Signaling
Technology according to the manufacturers’ instructions,
using phospho-GSK-3/b (Ser21/9) (37F11) rabbit monoclonal
antibodyt (9327) and mouse monoclonal ANTI-FLAG M2
antibody (F3165) from Sigma-Aldrich.
Phosphoinositide dot blot binding
analysis
FLAG immunoprecipitated AKT3 was eluted from the FLAG
beads using FLAG peptide (3 FLAG Peptide, F4799 Sigma-
Aldrich). PIP strip membranes were incubated with puriﬁed
AKT3 protein in 5ml of PBS-Tween 3% bovine serum albu-
min according to manufacturer’s instructions (P-6001 PIP
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STRIPS and P-6100 PIP Array, Echelon Biosciences). Binding
was detected by incubation with mouse monoclonal ANTI-
FLAG M2 antibody with chemiluminescence detection.
Statistics
P-values were calculated by use of Fisher’s exact test. A
P-value5 0.05 was considered statistically signiﬁcant.
Results
Clinical results
We identiﬁed AKT3 mutations in 14 new and four previ-
ously reported subjects, who collectively demonstrate a
wide spectrum of features (Riviere et al., 2012; Jansen
et al., 2015; Nellist et al., 2015). The clinical and molecular
data of our 14 new mutation-positive children, as well as
the previously published 11 patients, are summarized in
Table 1. The neuroimaging features of these children are
shown in Fig. 1. More comprehensive clinical, neuroima-
ging and molecular data are provided in Supplementary
Tables 2–5.
Neuroimaging features
First, we identiﬁed the mosaic p.E17K AKT3 mutation in
three children. The ﬁrst child (Patient LR15-262) had hemi-
megalencephaly with contralateral hemimicroencephaly
(Fig. 1A and B), and several cutaneous capillary malforma-
tions. This child was born in status epilepticus, had early
onset intractable epilepsy, and underwent hemispherectomy
at age 2 weeks. The second patient (Patient LR16-251)
harbouring the p.E17K mutation had a distinctive pheno-
type characterized by megalencephaly with multifocal but
bilateral cortical dysplasia (Fig. 1C and D). This child had
intractable epilepsy and passed away at the age of
10 months due to his deteriorating neurologic status. He
also had three capillary-lymphatic malformations. The third
child (Patient LR11-443) had a massively enlarged and dys-
plastic cerebral hemisphere with dysplasia identiﬁed in the
contralateral hemisphere as well. She also had a distinctive
vascular malformation on the lower leg characterized by
cutis marmorata telangiectatica congenita (CMTC)
(Jansen et al., 2015).
Second, we identiﬁed constitutional AKT3 mutations in
the remaining patients who can be clinically segregated
into three groups. The ﬁrst group includes children with
megalencephaly and polymicrogyria (n = 6). These children
had bilateral perisylvian polymicrogyria with variable ven-
triculomegaly (Fig. 1K–R). Among this group, one child had
hydrocephalus requiring neurosurgical shunting and Chiari
malformation requiring posterior fossa decompression
(Patient LR14-254; Fig. 1O and P). This child showed
global psychomotor delay at 2 years of age (due to
mainly language and motor delays). However, on preschool
evaluation at age 6 years, he showed normal cognitive skills
(Wechsler Preschool and Primary Scale of Intelligence,
WPPSI, score = 92). The second group consists of children
with megalencephaly and diffuse cortical dysplasia (also
termed dysplastic megalencephaly) with diffuse and bilateral
periventricular nodular heterotopia, a rare subgroup not
previously associated with any genes (n = 3) (Fig. 1G–J, W
and X). Patients LR16-301 and LP96-103 had extensive
heterotopia all along the ventricular surface (Fig. 1G–J),
whereas Patient LR14-112 had fewer and more discrete
heterotopia (Fig. 1W and X). Interestingly, all three patients
within this group had moderate-to-severe ventriculomegaly.
The third group of children with constitutional mutations
had megalencephaly with no or subtle (often unilateral) cor-
tical malformations and variable ventriculomegaly (n = 4)
(Fig. 1E, F and S–V). One child within this group had
megalencephaly, mildly thick corpus callosum and very
subtle cortical dysplasia with unilateral prominent in cor-
tical infolding into the perisylvian region (Patient LR12-470,
Fig. 1S and T). This child had mild learning issues and
communication problems. Another child within this group
(Patient LR13-008) was formally diagnosed with autism
spectrum disorders (ASD). Finally, one child (Patient
LR17-245), also within this group, had megalencephaly
only, with normal tone, and no developmental or
neurological issues at age 3 years (Supplementary material).
Neuropathological abnormalities
We examined the neuropathological features of megalence-
phaly-associated polymicrogyria in a previously reported
AKT3 mutation-positive child (Patient LR08-018) who
died unexpectedly at age 6 years. This boy had congenital
megalencephaly, bilateral perisylvian polymicrogyria, cere-
bellar tonsillar ectopia, somatic asymmetry and connective
tissue dysplasia (Mirzaa et al., 2012). He was identiﬁed to
have a de novo p.R465W mutation in AKT3 (Riviere et al.,
2012). This child passed away during sleep presumably due
to sudden unexpected death in epilepsy (SUDEP) (further
details provided in the Supplementary material).
Neuropathological analysis on post-mortem brain tissue re-
vealed that his brain weighed twice the normal weight of
adult brains (total weight = 2313 g) and was asymmetrically
enlarged (Fig. 2A and B). There was evidence of diffuse
cortical dysplasia with irregular hyperconvoluted gyri sug-
gestive of diffuse polymicrogyria, including anomalous
branching and fusion of gliotic layer 1. There were also
increased numbers of neurons in layer 6 and within the
white matter that appeared disorganized and maloriented.
However, neurons were not strikingly enlarged or dysplas-
tic, and no balloon cells were identiﬁed. The hippocampus
was grossly small and gliotic, and the dentate gyrus
exhibited focal ‘tram-track’ splitting of the granule
cell layer, typically associated with chronic epilepsy (Fig.
2B–Q).
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Somatic features
Several children in this series had vascular malformations
including CMTC (Patient LR11-443), capillary malforma-
tions and/or prominent veins (n = 5), and connective tissue
abnormalities including aplasia cutis congenita (n = 2). One
child (Patient LR13-008) had a prenatal stroke due to oc-
clusion of the right cerebral artery, with no evidence of
thrombophilia. Several patients had endocrine issues includ-
ing recurrent hypoglycaemia (n = 2) and hypothyroidism
(n = 1). Other notable features include immunological
issues including recurrent infections (n = 2). In one of
these patients (Patient LR14-112), recurrent infections
were due to combined IgA and IgE deﬁciency. Patient
LR13-008 also had severe vitamin A malabsorption
(Supplementary Table 4).
Molecular results
All 14 AKT3 mutations reported in this series, and our
previously reported four mutations, were identiﬁed or con-
ﬁrmed by targeted next generation and/or Sanger sequen-
cing. Levels of mosaicism, tissues tested and methods of
detection are provided in Supplementary Table 5.
Table 1 Summary of the clinical and molecular findings of AKT3 mutation-positive patients (n = 24) [AKT3:
NM_005465.4]
Subject ID Diagnosis cDNA
change
Amino acid
change
Functional
domain
Inheritance Mutation type, AAP
(tissue)
Mosaic AKT3 mutations (n = 5)
LR15-262 DMEG/HMEG c.49G4A p.Glu17Lys PH NA Mosaic, 8–14% (brain, skin)
HME-1565 HMEG c.49G4A p.Glu17Lys PH De novo Mosaic, 16–30% (brain)
(Lee et al., 2012)
Patient 3 DMEG/HMEG c.49G4A p.Glu17Lys PH De novo Mosaic, 35% (brain)
(Poduri et al., 2012)
LR11-443 DMEG/HMEG c.49G4A p.Glu17Lys PH De novo Mosaic, 1–18% (brain, skin)
(Jansen et al., 2015)
LR16-251 DMEG/multifocal c.49G4A p.Glu17Lys PH NA Mosaic, 1.8% (skin)
Constitutional AKT3 mutations (by functional domain; n = 20)
Patient MEG c.118G4A p.Glu40Lys PH De novo Constitutional
(Takagi et al., 2017)
LR16-372 MEG c.159C4A p.Asn53Lys PH De novo Constitutional
LR16-301 MEG-PMG-PNH c.161T4A p.Phe54Tyr PH De novo Constitutional
LR17-245 MEG c.237G4T p.Trp79Cys PH De novo Constitutional
LP96-103 MEG-PMG-PNH c.548T4A p.Val183Asp Kinase De novo Constitutional
LR12-314 MEG-PMG-PNH c.548T4A p.Val183Asp Kinase De novo Constitutional
(Nellist et al., 2015)
LR11-354 MEG-PMG c.686A4G p.Asn229Ser Kinase De novo Constitutional
(Riviere et al., 2012)
Patient MEG-PMG c.686A4G p.Asn229Ser Kinase De novo Presumed constitutionala
(Harada et al., 2015)
Patient 2 MEG-PMG (MCAP) c.686A4G p.Asn229Ser Kinase De novo Constitutional
(Nakamura et al., 2014)
Patient 1 MEG-PMG c.686A4G p.Asn229Ser Kinase De novo Constitutional
(Negishi et al., 2014)
LR13-041 MEG-PMG c.803T4C p.Val268Ala Kinase De novo Presumed constitutionala
LR14-271 MEG-PMG c.964G4A p.Asp322Asn Kinase De novo Constitutional
LR14-254 MEG-PMG c.964G4A p.Asp322Asn Kinase De novo Constitutional
LR12-412 MEG-PMG c.1393C4T p.Arg465Trp C-terminal NA Constitutional
LR14-025 MEG-PMG c.1393C4T p.Arg465Trp C-terminal De novo Constitutional
LR12-470 MEG c.1393C4T p.Arg465Trp C-terminal De novo Presumed constitutionala
LR13-008 MEG-autism c.1393C4T p.Arg465Trp C-terminal De novo Presumed constitutionala
LR14-112 MEG-PMG-PNH c.1393C4T p.Arg465Trp C-terminal De novo Constitutional
LR08-018 MEG-PMG c.1393C4T p.Arg465Trp C-terminal De novo Constitutional
(Riviere et al., 2012)
PMG-3801 MEG-PMG c.1393C4T p.Arg465Trp C-terminal De novo Constitutional
(Jamuar et al., 2014)
AAP = alternate allele percentage (i.e. mutation level); DMEG = dysplastic megalencephaly; HMEG = hemimegalencephaly; MEG = megalencephaly; NA = not available;
PH = pleckstrin homology; PMG = polymicrogyria; PNH = periventricular nodular heterotopia.
aMutations are presumed to be constitutional or germline due to one tissue only being molecularly analysed, with no evidence of mosaicism in the analysed tissue.
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Figure 1 Brain MRIs of AKT3 mutation-positive children. (A and B) Brain MRI of Patient LR15-262 showing markedly enlarged and
dysplastic right cerebral hemisphere with diffuse cortical dysplasia and dysmyelination consistent with hemimegalencephaly. The contralateral
hemisphere is markedly decreased in size with areas of cortical dysplasia (hemimicroencephaly). (C and D) Images of Patient LR16-251 showing
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Mutations in two children with megalencephaly and mega-
lencephaly with heterotopia (Patients LR16-372 and LR16-
301) were identiﬁed by clinical whole exome sequencing
(WES) on the proband, followed by targeted parental mu-
tation analysis by Sanger sequencing.
The p.E17K mutation detected in our three patients was
low-level mosaic, as mentioned previously. In Patient LR15-
262, the alternate allele percentage (AAP) was 12.6–13.9%
in affected brain tissue from the more dysplastic hemisphere
resected during epilepsy surgery. Interestingly, the mutation
was detectable in skin ﬁbroblasts from normal-appearing
skin (at 8.6–9.5% AAP) but was undetectable in peripheral
blood-derived DNA. The mutation in Patient LR11-443 was
present in 20–36% of cells from several affected brain re-
gions from the more severely affected hemisphere. It was
also detectable at a very low level (AAP 1.3%) from skin
ﬁbroblast-derived DNA (also from healthy-appearing skin).
In Patient LR16-251 who had bilateral multifocal cortical
dysplasia, the p.E17K mutation was present at a very low
level in skin ﬁbroblasts (AAP 1.8%). This child did not
undergo epilepsy surgery due to his bilateral malformations,
and no post-mortem brain tissue was available for molecular
analysis. The other AKT3 mutations identiﬁed in our series
were all constitutional, and were conﬁrmed to be de novo
when parental DNA was available. Five novel constitutional
AKT3 mutations—p.N53K, p.F54Y, p.V268A, p.D322N,
and p.W79C—were detected in six children in this series.
Mutations in two patients (Patients LR12-470 and LR13-
008) are presumed to be constitutional as DNA derived
from saliva was used for molecular analysis, and peripheral
blood-derived DNA was unavailable.
Functional analysis of AKT3 mutants
With the exception of p.R465W, which localizes to the C-
terminal region of AKT3, the remaining mutations are
within the pleckstrin homology domain or the catalytic
kinase domain (Fig. 3A). Kinase activity analysis following
ectopic overexpression clearly showed that all identiﬁed
patient mutations caused increased activity compared to
wild-type AKT3 (Fig. 3B and C). The p.E17K pleckstrin
homology mutant domain has previously been shown to
result in elevated kinase activity and to be oncogenic via
enhanced pathological localization to the plasma membrane
(Carpten et al., 2007; Parikh et al., 2012). As the pleckstrin
homology domain is critical for phospholipid binding and
consequent kinase activation, we assessed whether the
novel mutations localized in the pleckstrin homology
domain described here (p.N53K and p.F54Y) have a simi-
lar impact upon phospholipid binding as p.E17K (Park
et al., 2008; Parikh et al., 2012). We used dot-blot analysis
using an array of different phospholipids immobilized on
wild-type AKT3. Indeed, these pleckstrin homology mutant
domains exhibited markedly elevated binding to phospha-
tidylinositol-(3,4)-biphosphate [PtdIns(3,4)P2] in particular,
which is a key plasma membrane constituent and substrate
of phosphatidylinostitol-3-kinase.
Discussion
Malformations of cortical development comprise a wide
range of disorders characterized by aberrant neuronal mi-
gration, proliferation and organization, and result in signiﬁ-
cant childhood morbidity and mortality (Barkovich et al.,
2012). A growing spectrum of these malformations is
now known to be caused by germline or mosaic mutations
of genes within the PI3K-AKT-MTOR signalling
network (Mirzaa et al., 2013; Jamuar et al., 2014;
Mirzaa and Poduri, 2014). The post-zygotic (mosaic) mu-
tations are most readily identiﬁed in affected (surgically
removed) brain tissues (Mirzaa et al., 2016b)
(Supplementary Fig. 1).
AKT3 is one of three AKT homologues (AKT1–3), the
central effector of the PI3K-AKT-MTOR pathway (Yang
et al., 2004). Mutations of AKT1 and AKT2 have been
identiﬁed in somatic overgrowth disorders such as Proteus
syndrome and in somatic overgrowth with hypoglycaemia,
respectively (Hussain et al., 2011; Lindhurst et al., 2011). To
date, reported children with these phenotypes all harboured
the p.E17K mutation in these respective genes. The paralo-
gous mutation in the brain-enriched isoform, AKT3, has
Figure 1 Continued
multifocal areas of dysplastic cortex in the perisylvian, frontal, temporal and occipital regions (arrows). (E and F) Images of Patient LR16-372
showing a thick and dysplastic corpus callosum and deeply infolded perisylvian regions. (G–I) Images of Patient LR16-301 showing striking
megalencephaly, ventriculomegaly, stretched but thick corpus callosum, diffuse polymicrogyria with deep infolding in the right occipital lobe, and
bilateral periventricular nodular heterotopia (arrowheads). (J) Image of Patient LP96-103 showing diffuse bilateral perisylvian polymicrogyria,
ventriculomegaly, cavum septum pellucidum et vergae and diffuse periventricular nodular heterotopia (arrowheads). (K and L) Images of Patient
LR13-041 showing a large cerebellum with cerebellar tonsillar ectopia, bilateral polymicrogyria predominantly in the perisylvian region (more
severe on the right, arrows) with dysmyelination. (M and N) Images of Patient LR14-271 showing diffuse megalencephaly with a thick corpus
callosum and deep infolding in the perisylvian region suggestive of polymicrogyria (arrows). (O and P) Images of Patient LR14-254 showing diffuse
megalencephaly, thick corpus callosum and bilaterally diffuse infolding of the perisylvian region suggestive of polymicrogyria (arrows). (Q and R)
Images of Patient LR14-025 showing megalencephaly, thick corpus callosum and bilateral diffuse polymicrogyria with increased extra-axial space.
(S and T) Images of Patient LR12-470 showing megalencephaly and thick corpus callosum. This patient also had deep infolding in the right
perisylvian region suspicious for polymicrogyria, with very limited involvement (arrows). (U and V) Images of Patient LR13-008 showing diffuse
megalencephaly and possible area of cortical dysplasia in the right perisylvian region. (W and X) Images of Patient LR14-112 showing diffuse
megalencephaly, bilateral perisylvian polymicrogyria and bilateral ventriculomegaly.
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Figure 2 Pathologic examination of the brain of Patient LR08-018 (p.R465W). (A) Brain size. Graph depicting the largest paediatric
brain sizes (in grams) previously reported in the literature (green bars) relative to the brain size of Patient LR08-018 (with the p.R465W mutation,
red bar) demonstrating that brain size for this patient is markedly larger than these patients (Wilson, 1934). The graph is an adaptation of the
human brain growth diagram from the Smithsonian Institute (http://humanorigins.si.edu/human-characteristics/brains). The graph shows the
periods of rapid brain growth (in orange) plus the period of decreased brain growth (in blue) followed by the plateau in brain growth.
(B–E) Cerebral hemispheres. The massive brain (2313 g; approximately twice normal weight for age) was asymmetrically enlarged. The left
hemisphere (B and C) weighed 941 g, and the right (D and E) weighed 1128 g. Primary fissures such as the Sylvian (sy), central (ce), postcentral
(pc), and calcarine (ca) sulci were recognizable, but secondary and tertiary sulci were abnormal. Gyri appeared irregular and overall hypercon-
voluted. The corpus callosum was present including genu (ge), body, and splenium (sp). The anterior commissure (ac) was present but small.
White asterisks: artefactual disruption of hemispheres due to brain removal and transport. Black asterisks: torn junction of hemispheres and
midbrain. All panels are at the same magnification. (F–I) Hyperconvolution and polymicrogyria in cerebral cortex. (F) Brain slice through parietal
cortex showed redundant folds of cortex extending deep into white matter. (G) Histological section (haematoxylin and eosin) through the same
region showed relatively sharp grey-white junctions. (H) Inferior temporal cortex exhibited features of polymicrogyria, including anomalous
branching and fusion of gliotic layer 1 (GFAP immunohistochemistry). (I) Layer 1 fusion and branching were confirmed by NeuN immunohis-
tochemistry. (J–N) Abnormal layering of cerebral cortex, and excessive white matter neurons. In foci not involved with polymicrogyria, such as
right posterior perisylvian cortex, cortical layering was moderately disorganized. (J) Cortical layers were identified based on cell size and density.
NeuN immunohistochemistry. (K) Layer 1 was cell-sparse and contained only small neurons. (L) Layer 4 contained typical small (granular)
neurons. (M) Layer 6 neurons were particularly disorganized and maloriented. (N) Increased neurons in white matter (wm). Interestingly, neurons
in this case were not strikingly enlarged or dysplastic, nor were any balloon cells present. (O–Q) Hippocampal and brainstem abnormalities of
Patient LR08-018. (O) The left hippocampus was very small and gliotic, and the hippocampal sulcus (arrowhead) was open, suggesting a deficiency
of perforant pathway fibres, which would normally cross the fused sulcus. GFAP immunohistochemistry. (P) Histologically, the dentate gyrus
exhibited focal ‘tram-track’ splitting of the granule cell layer (arrowhead; enlarged 2 in inset), a finding usually associated with chronic epilepsy.
(Q) The upper medulla showed marked asymmetry of the pyramidal tract, essentially limited to one side (arrowhead). The adjacent inferior olives
were moderately hypoconvoluted (haematoxylin and eosin).
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been identiﬁed in mosaic form in children with hemimega-
lencephaly (Lee et al., 2012; Poduri et al., 2012; Jansen
et al., 2015). Constitutional mutations of AKT3 have been
identiﬁed in children with diffuse megalencephaly in syn-
dromic forms such as megalencephaly polymicrogyria poly-
dactyly hydrocephalus (MPPH) syndrome, and somatic
duplications of the AKT3 locus have been identiﬁed in a
few children with hemimegalencephaly and diffuse megalen-
cephaly without cortical dysplasia (Wang et al., 2013;
Chung et al., 2014; Conti et al., 2015; Hemming et al.,
2016). To date, 11 children have been reported with
AKT3 mutations in case reports of one or a few individuals.
Here, we report on the clinical and neuroimaging spectrum
of 14 children identiﬁed to have constitutional or mosaic
Figure 3 Analysis of AKT3 activity in vitro. (A) The primary structure of AKT3 showing the relative positions of the pleckstrin homology
(PH) domain for lipid binding the catalytic kinase domain and C-terminal (C-ter) region. Mutations identified to date are shown along with the
numbers of patients with these mutations in brackets. (B) Catalytic kinase domain and C-terminal localizing patient-derived AKT3 mutations are
associated with elevated kinase activity. Ectopically expressed wild-type (WT) AKT, a kinase dead variant K177M, the E17K activating pleckstrin
homology domain mutant and various patient mutants were assessed for kinase activity using a GSK3b peptide as a substrate in an ex vivo kinase
assay. The upper panel shows immune detection of phosphorylated GSK3b peptide following western blotting with anti-phospho-GSK3b (Ser9/
Ser21) antibody. The patient mutants all exhibit elevated phospho-activity compared to wild-type. The graph depicts quantitation of phospho-
GSK3b (Ser9/Ser21) signal (a.u. = arbitrary units). Error bars represent mean  SD (n = 4), P-values were determined using Student’s t-test.
(C) Pleckstrin homology domain localizing patient mutations are associated with elevated kinase activity and altered phospholipid-binding profile.
Left panels show western blot analysis of phospho-GSK3b (Ser9/Ser21) of ectopically expressed wild-type, K177M kinase dead and three
pleckstrin homology domain patient mutants; E17K, N53K and F54Y. The graph depicts quantitation of phospho-GSK3b (Ser9/Ser21) signal. Error
bars represent mean  SD (n = 4), P-values were determined using Student’s t-test. The bottom panels depict PIP-membranes seeded with various
lipids and phospholipids for dot blot binding analysis. Ectopically expressed FLAG-tagged wild-type and AKT3 pleckstrin homology domain
mutants were incubated with the PIP Strips and bound protein detected by western blotting using anti-FLAG. All three pleckstrin homology
domain mutants exhibit altered and elevated binding to specific phospholipids compared to wild-type. DMEG = dysplastic megalencephaly;
HMEG = hemimegalencephaly; LPA = lysophophatidic acid; LPC = lysophosphocholine; MEG = megalencephaly; P = phosphate; PA = phosphatidic
acid; PC = phosphatidylcholine; PE = phosphatidylethanolamine; PMG = polymicrogryria; PS = phosphatidylserine; PtdIns = phosphatidylinositol;
S1P = sphingosine-1-phosphate.
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AKT3 mutations, including six children with ﬁve novel
AKT3 mutations, adding to our previously published data
on four AKT3 mutation-positive children (Riviere et al.,
2012; Jansen et al., 2015; Nellist et al., 2015). Using
in vitro kinase assay, we show that these mutations consti-
tutively activate AKT3.
Our series provides several important insights into the
clinical and molecular spectrum of mutations associated
with this critical gene. First, our series shows that there
are important and emerging genotype–phenotype correl-
ations of AKT3 mutations whereby the highly mosaic
p.E17K mutation is associated with very segmental brain
malformations (i.e. hemimegalencephaly), whereas constitu-
tional mutations are associated with more widespread cor-
tical malformations with bilateral (but often asymmetric)
ﬁndings (P5 0.05; Supplementary Table 6). We describe
two new patients with the recurrent, mosaic p.E17K muta-
tion. Importantly, one of these children had a novel pheno-
type characterized by multifocal and bilateral focal cortical
dysplasia lacking a severity gradient between right and left
hemispheres, unlike all previously reported children with
the p.E17K AKT3 mutation who had highly asymmetric
cortical dysplasia (regarded as ‘classic hemimegalence-
phaly’). Second, our series substantially broadens the clin-
ical spectrum of constitutional AKT3 mutations to include
diffuse, most often perisylvian, polymicrogyria and periven-
tricular nodular heterotopia (PNH), with hydrocephalus
and cerebellar tonsillar ectopia occurring in a subset of in-
dividuals. Therefore, this report establishes AKT3
mutations as the ﬁrst genetic cause of megalencephaly
with PNH and polymicrogyria; a clinical phenotype previ-
ously reported as a distinct entity (Wieck et al., 2005).
Importantly, our series further shows that constitutional
AKT3 mutations, which can also occur in the pleckstrin
homology domain where p.E17K mutation localizes, are
associated with diffuse megalencephaly without cortical
malformations, with normal cognitive development in two
patients, one of whom had autistic features—resembling the
PTEN-hamartoma tumour syndrome—and suggesting that
mutations of the AKT3 gene are associated with autism
spectrum disorders (ASD).
Collectively our data suggest that there are several distinct
brain malformation syndromes caused by AKT3 mutations
that can be broadly categorized into: (i) highly segmental
cortical dysplasia (including hemimegalencephaly) and vas-
cular malformations associated with the mosaic p.E17K
AKT3 mutation. We believe that this comprises a clinically
recognizable subgroup with megalencephaly, extensive focal
cortical dysplasia (either hemimegalencephaly or bilateral,
multifocal FCD), and cutaneous vascular malformations;
(ii) megalencephaly-polymicrogyria with frequent asym-
metry and occasionally patchy somatic ﬁndings [as occurs
in MPPH and megalencephaly-capillary malformation syn-
drome (MCAP)]; (iii) megalencephaly-polymicrogyria with
periventricular nodular heterotopia (PNH); and (iv) mega-
lencephaly with normal or minimal cortical dysplasia, and
ASD or autistic features (Fig. 4). We believe this clinical
stratiﬁcation is diagnostically important as resection of
Figure 4 Diagram showing the spectrum of AKT3-associated phenotypes. Several groups of partially overlapping developmental brain
disorders are associated with AKT3 mutations that include the following phenotypes (i) focal malformations of cortical development that are highly
segmental [e.g. focal cortical dysplasia (FCD), hemimegalencephaly (HMEG), dysplastic megalencephaly DMEG; orange]; (ii) bilateral polymicro-
gyria (PMG) (purple) with or without ventriculomegaly or hydrocephalus (VMEG-HYD; light purple), and heterotopia (HET; blue); (iii) diffuse
megalencephaly with intellectual disability (ID) and/or autistic features (AUT) with subtle or no cortical dysplasia (green). *Of note, MCAP and
MPPH fit within the second group of AKT3-related disorders, from the brain phenotype perspective. MCAP can be further clinically distinguished
by somatic findings (somatic overgrowth, vascular or lymphatic abnormalities), and MPPH by the occurrence of polydactyly in a subset of affected
individuals. A general molecular diagnostic workflow for megalencephaly has been proposed (Supplementary Fig. 1). OFC = orbitofrontal cortex.
Mutations of AKT3 BRAIN 2017: 140; 2610–2622 | 2619
Downloaded from https://academic.oup.com/brain/article-abstract/140/10/2610/4107301
by University of Szeged user
on 01 February 2018
epileptic brain tissue is likely to be clinically warranted for
children in Group 1, but less likely in Groups 2 and 3.
Hydrocephalus and Chiari malformations, on the other
hand, are complications likely to occur in children with
diffuse megalencephaly occurring in Groups 2 and 3, de-
pending on the severity of ventriculomegaly and cerebellar
tonsillar enlargement, respectively.
Seizures are a common feature of our cohort and have
been reported in Akt mouse models with activating Akt3
mutations (Tokuda et al., 2011; Baek et al., 2015). Seizures
are especially severe in children with the p.E17K mutation,
likely due to the severity of the underlying cortical malfor-
mation. However, one of our patients (Patient LR08-018)
with the constitutional p.R465W AKT3 mutation had in-
tractable epilepsy as well, and may have had SUDEP; an
interesting association that suggests that aggressive anti-epi-
lepsy treatment and management may be necessary with this
spectrum. This association will require further investigation
in future children identiﬁed to have AKT3 mutations.
With regards to non-neurological ﬁndings, our series
shows that vascular malformations are common with
AKT3-related disorders and may provide useful diagnostic
clues. Vascular malformations in all AKT3 mutation pa-
tients reported to date were patchy, few, and best charac-
terized as capillary malformations, although one patient
(Patient LR11-443) had CMTC, which is clinically distinct
from capillary malformations. Unlike PIK3CA-related dis-
orders, these vascular malformations were not associated
with marked somatic overgrowth, lipomatosis, or soft
tissue hypertrophy (Keppler-Noreuil et al., 2015; Mirzaa
et al., 2016a). The occurrence of a prenatal stroke in one
child is clinically noteworthy, as prenatal strokes and/or
thrombophilia have been reported in some children with
MCAP caused by PIK3CA mutations, as well as in
Proteus syndrome caused by AKT1 mutations (Slavotinek
et al., 2000; Mirzaa et al., 2012).
Two children in our series also had hypoglycaemia.
These data add to a previous report of hypoglycaemia
with AKT3-related disorders and further support this
gene’s roles in glucose regulation (Nellist et al., 2015).
Mutations of AKT2 are known to cause asymmetric over-
growth with hypoglycaemia, exemplifying the critical role
of this gene in insulin-dependent glucose regulation (Cho
et al., 2001; Hussain et al., 2011; Arya et al., 2014; Garg
et al., 2015). While the cause of hypoglycaemia in our pa-
tients remains undetermined, this potential association war-
rants further studies as this may have important clinical
implications for AKT3 mutation-positive children identiﬁed
in the future as well.
Our functional analysis of the patient mutations showed a
robust elevation of catalytic kinase activity. This is consistent
with the elevated PI3K-AKT-MTOR signalling underlying
these types of brain overgrowth disorders. Furthermore,
pleckstrin homology domain-localizing mutations all
exhibited elevated phospholipid binding compared to
wild-type. This feature of the p.E17K mutation has been
proposed to explain why this mutation is oncogenic and
recurrent in a wide range of cancers (Carpten et al.,
2007). Considering the similar phospholipid binding proﬁle,
we have uncovered here for p.N53K and p.F54Y compared
to p.E17K, our ﬁndings suggest that careful monitoring of
such individuals for cancers is warranted, although formal
cancer surveillance guidelines cannot be proposed at this
time due to lack of clinical evidence for these complications.
Among the limitations of our study was the ability to
determine whether mutations of other genes (i.e. a two-hit
phenomenon) are present in any of the patients in our
series, and that may also explain the clinical heterogeneity
of the brain phenotype. Indeed, this phenomenon has long
been suspected for focal malformations of cortical develop-
ment, especially PI3K-AKT-MTOR related disorders, and
has been shown for speciﬁc ones such as the cortical
tubers of tuberous sclerosis, for example (Crino et al.,
2010). Therefore, this phenomenon is clearly of relevance
to this spectrum of developmental brain disorders.
However, there are several challenges towards identifying
second hit mosaicism in this patient population. The ﬁrst
is the accessibility of affected tissues (i.e. brain) for molecu-
lar analysis, and the yield of DNA from these tissues. Only
one of our two patients with focal malformations of cortical
development due to AKT3 mutations underwent epilepsy
surgery allowing molecular analysis on affected brain tis-
sues. Second, the depth of coverage of the molecular
method used. The ability to detect low-level mutations re-
quires ultra-deep sequencing. Therefore, methods such as
the ones we have used (deep next generation sequencing)
would be necessary. To achieve the necessary depth of
coverage, these methods often must be targeted (by testing
a panel or subset of genes), and therefore, performing more
global genomic assays to look for second hit mosaicism
broadly (such as by whole exome or whole genome sequen-
cing) may either not be feasible or technically possible (due
to insufﬁcient DNA yield). Finally, the most ideal approach
to delineate the occurrence of second hit mosaicism would
be to isolate speciﬁc cell populations by single cell sequen-
cing. Therefore, while we were unable to detect the presence
of second hit mosaicism in the individuals reported in our
study due to some of challenges highlighted above, we an-
ticipate that future advances in our molecular methods will
undoubtedly improve our ability to detect second hit mosai-
cism in this spectrum of disorders.
In summary, we show that activating mutations of AKT3
are associated with a much broader spectrum of develop-
mental brain disorders in children, with several clinical
phenotypes determined partially by the type of mutation
and level of mosaicism. Our series suggests that the
mosaic p.E17K AKT3 mutation is associated with highly
segmental brain malformations that may warrant surgical
resection to achieve seizure control, whereas constitutional
mutations of AKT3 are associated with bilateral brain mal-
formations including bilateral perisylvian polymicrogyria,
periventricular nodular heterotopia and megalencephaly
without cortical dysplasia. In this series, we also report
on the neuropathological abnormalities caused by a
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constitutional AKT3 mutation in one of the largest docu-
mented brain sizes in the paediatric population, to date.
Our data also suggest that monitoring for hypoglycaemia
in affected individuals may also be warranted.
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